Clinical Trial Update: A Bioequivalence Study of SKF101804 Cefixime Versus Cefixime Reference Formulation in Healthy Adults Under Fasting Conditions [Phase 1]

View source ↗

Summary

A Phase 1 bioequivalence study comparing SKF101804 cefixime to a cefixime reference formulation in healthy adults under fasting conditions has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchitis
• Gonorrhea
• Otitis Media
• Pharyngitis
• Pneumonia
• Sinusitis
• Tonsillitis
• Urinary Tract Infection

Drugs mentioned

• Cefixime (reference formulation) (cefixime)
• SKF101804 Cefixime (cefixime)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Bacterial | Phase 1 | Status: WITHDRAWN